INTERVIEW: Ding plans Betta chances for Conmana in China
This article was originally published in Scrip
Executive Summary
China is home to the world's largest aging population – approximately 200 million people over the age of 60. As such, chronic diseases such as diabetes and cancer have been the target for big pharma companies in the country. Among them is Betta Pharma (Betta), a private company founded in 2003 by Dr Lieming Ding, a former board-certified physician in the US, and his partners.
You may also be interested in...
Chinese Appetite For Medtech Could Shrink In Face Of Uncertainty
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China’s Big And Small Next-Gen Sequencing Players Ride The Precision Medicine Wave
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
China's new biosimilars guideline: more flexibility, but stricter in parts
The China Food and Drug Administration has released the final version of its biosimilars guideline1.